RAF1 and cancer: To address the limitations of BRAFi therapies, a study [98••] using vemurafenib-based PROTACs achieved low nanomolar degradation of all classes of BRAF mutants but WT RAF and outperformed vemurafenib in inhibiting cancer cell growth.